Journal
NEUROSCIENCE
Volume 132, Issue 1, Pages 123-135Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuroscience.2004.12.025
Keywords
dementia; drug screen; A beta peptide; arctic; conformational
Categories
Ask authors/readers for more resources
We have developed models of Alzheimer's disease in Drosophila melanogaster by expressing the A beta peptides that accumulate in human disease. Expression of wild-type and Arctic mutant (Glu22Gly) A beta(1-42) peptides in Drosophila neural tissue results in intracellular A beta accumulation followed by non-amyloid aggregates that resemble diffuse plaques. These histological changes are associated with progressive locomotor deficits and vacuolation of the brain and premature death of the flies. The severity of the neurodegeneration is proportional to the propensity of the expressed A beta peptide to form oligomers. The fly phenotype is rescued by treatment with Congo Red that reduces A beta aggregation in vitro. Our model demonstrates that intracellular accumulation and non-amyloid aggregates of A beta are sufficient to cause the neurodegeneration of Alzheimer's disease. Moreover it provides a platform to dissect the pathways of neurodegeneration in Alzheimer's disease and to develop novel therapeutic interventions. (c) 2005 IBRO. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available